GlassScriptPhysician profile
Ramin Gabbai
NPI 1457417248
$1,724.22
in general payments reported to CMS, 2019-2025
12 companies · $208 in 2025
The $208 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $79.29 · 2021: $72.26 · 2022: $355 · 2023: $372 · 2024: $375 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $954.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $378.53 | 2019-2023 | Lokelma, Farxiga |
| Ardelyx, INC. | $214.55 | 2024 | Xphozah 30 Mg, Ibsrela |
| Amgen INC. | $212.31 | 2019-2022 | |
| Akebia Therapeutics INC | $174.61 | 2025 | Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $145.66 | 2023 | |
| Glaxosmithkline, LLC. | $144.05 | 2023-2024 | Jesduvroq |
| Aurinia Pharma U.S., INC. | $134.34 | 2022 | |
| Alexion Pharmaceuticals, INC. | $127.50 | 2024 | |
| Horizon Therapeutics Plc | $108.40 | 2020-2021 | |
| Abbvie INC. | $33.87 | 2025 | |
| Radius Health, INC. | $31.05 | 2019 | |
| Fresenius Kabi USA, LLC | $19.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramin Gabbai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.